May 18, 2020

COVID-19 Vaccine Shipped, and Drug Trials Start

FEBRUARY 25, 2020
Moderna Therapeutics, a biotech company based in Cambridge, Mass., has shipped the first batches of its COVID-19 vaccine. The vaccine was created just 42 days after the genetic sequence of the COVID_19 virus, called SARS-CoV-2, was released by Chinese researchers in mid-January. The first vials were sent to the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) in Bethesda, MD, which will ready the vaccine for human testing as early as April.
NIH scientists also began testing an antiviral drug called remdesivir that had been developed for Ebola, on a patient infected with SARS-CoV-2. The trial is the first to test a drug for treating COVID-19, and will be led by a team at the University of Nebraska Medical Center. The first patient to volunteer for the ground-breaking study is a passenger who was brought back to the US after testing positive for the disease aboard the Diamond Princess. Others diagnosed with COVID-19 who have been hospitalized will also be part of the study.
Remdesivir showed encouraging results among animals infected with two related coronaviruses, one responsible for severe acute respiratory syndrome (SARS) and another for causing Middle East respiratory syndrome (MERS). Volunteers will be randomly assigned to receive either the drug or a placebo intravenously for 10 days, and they will have blood tests and nose and throat swabs taken every two days to track the amount of virus in their bodies. Even if the drug shows some efficacy in keeping blood levels of SARS-CoV-2 from growing, it could help to contain spread of the infection.
Moderna’s vaccine against COVID-19 was developed in record time because it’s based on a relatively new genetic method that does not require growing huge amounts of virus. Instead, the vaccine is packed with mRNA, the genetic material that comes from DNA and makes proteins. Moderna loads its vaccine with mRNA that codes for the right coronavirus proteins which then get injected into the body. Immune cells in the lymph nodes can process that mRNA and start making the protein in just the right way for other immune cells to recognize and mark them for destruction.
As Dr. Stephen Hoge, president of Moderna, told TIME earlier this month, “mRNA is really like a software molecule in biology. So our vaccine is like the software program to the body, which then goes and makes the [viral] proteins that can generate an immune response.” That means that this vaccine method can be scaled up quickly, saving critical time when a new disease like COVID-19 emerges and starts infecting tens of thousands of people.

Post Polio Litaff, Association A.C _APPLAC Mexico

Respiratory and Sleep problems in Post-Polio

Post-polio syndrome  [13][14]


  • Respiratory problems in PPS are an important cause of symptoms and complications, including sleep disorders.
  • They may be under-diagnosed or inadequately assessed.
  • Treatment can improve both quality of life and prognosis.


Respiratory problems in PPS may be due

to one or more of:
  • Respiratory muscle weakness.
  • Bulbar impairment - this may affect control of the upper airway or the respiratory cycle. If the upper airway is affected, there may be obstructive sleep apnoea.
  • Skeletal deformity - scoliosis or chest wall stiffness.
  • Other pathology - eg, chronic obstructive pulmonary disease (COPD), asthma, obesity.
  • Aspiration - if swallowing is affected.
All these are likely to worsen during sleep. The pattern of respiratory impairment may be hypoventilation, obstructive sleep apnoea, or both.


Respiratory failure can develop insidiously - symptoms may be subtle or unnoticed. Breathlessness may not be a symptom in patients with limited mobility. Possible symptoms are:
  • Sleep disruption, eventually leading to insomnia, daytime sleepiness or fatigue.
  • Morning headaches, irritability, poor concentration, anxiety or depression.
  • Abnormal sleep movements, nocturnal confusion, vivid dreams.
  • Breathlessness which may be positional.
  • Weak cough, and chest infections.


These may be subtle - possible signs are:
  • Unexplained tachypnoea.
  • Use of accessory muscles.
  • Abdominal paradox - this is inward movement of the abdomen on inspiration while the upper chest expands.
    • May be best seen with the patient supine during a sniff manoeuvre. When upright, it can be missed, as the diaphragm passively descends at the beginning of inspiration.
  • Severe, untreated nocturnal hypoxaemia can cause pulmonary hypertension, giving signs such as raised JVP and ankle oedema.

Assessment of respiratory problems

  • Listen to the patient's story and preferences.
  • Assess:
    • Voice and cough.
    • Chest deformity.
    • Observe patients in realistic situations - eg, doing repeated tests or actions, and doing everyday actions in which they may be using the necessary breathing muscles to achieve another task.
  • Investigations:
    • Peak flow and cough peak flow.
    • Spirometry:
      • Both seated AND supine spirometry are needed.
      • A sensitive indicator of respiratory muscle weakness is reduction in maximal inspiratory pressure.
    • Oximetry (and possibly capnography).
    • Sleep study (polysomnogram).
    • ECG and CXR if appropriate.
    Full sets of lung function tests and arterial blood gases may not be helpful in this scenario, unless intrinsic lung disease is suspected.

Management of respiratory problems

There are various options - choice will depend on the patient's individual situation and preferences.
Night-time mechanical ventilation is often used. This helps by resting the respiratory muscles at night, and preventing deterioration of respiratory function during sleep. It also treats the secondary sleep disorder.

Supportive measures include:
  • Not smoking.
  • Avoiding sedatives and alcohol.
  • Optimal weight and nutrition.
  • Pneumococcal and influenza vaccination.
  • Postural support if needed.
  • Prompt treatment of chest infections.
  • Techniques such as assisted cough or glossopharyngeal breathing ('frog breathing').
  • Chest expansion exercises.
Assisted breathing options are:
  • Non-invasive ventilation (NIV), also called non-invasive intermittent positive pressure ventilation (NIPPV), is often useful - see box below.
  • Rocking bed:
    • This helps breathing by rocking a patient consecutively head up and head down. It is surprisingly effective, especially where muscle weakness is mainly diaphragmatic.
  • Pneumobelt:
    • This gives intermittent abdominal pressure ventilation and is useful for daytime assistance.
  • Negative pressure ventilation:
    • Examples are tank ventilators (iron lung), jacket ventilators (Tunnicliffe), and cuirass ventilators. The devices are cumbersome, and mainly used where NIV is not tolerated, or to provide 'respite' from NIV
  • Tracheostomy ventilation.

Non-invasive ventilation and 'bi-levels' explained[13][14]

NIV increases alveolar ventilation. It is provided by a portable ventilator and a tightly-fitting nasal or facial mask or nasal 'pillow'.
  • NB: NIV is NOT the same as continuous positive airway pressure (CPAP). CPAP is useful for obstructive sleep apnoea because it maintains the upper airway. It is not normally indicated for hypoventilation from respiratory muscle weakness.
People with neuromuscular disease may have difficulty breathing in, so require NIV with higher inspiratory than expiratory pressures. This can be provided using a 'bi-level' ventilator:
  • Bi-level ventilators were developed by modifying CPAP. The inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP) settings are adjusted separately.
  • The difference between IPAP and EPAP is called the span.
  • For example, a patient may require an IPAP of 14 and an EPAP of 3.
  • Sensitive flow triggers enable normal breathing to be supported. There may be a back-up control to provide ventilation if respiratory effort fails to trigger a breath.
The symptoms of post-polio syndrome are slowly progressive, with periods of stability lasting 3-10 years.
Prevention of acute polio infection is discussed elsewhere (see separate article onPoliomyelitis).

Prevention of PPS is not much discussed in the literature. Given the various known contributing factors, it seems possible that PPS problems might be reduced by:
  • Careful management of exercise and daily living activities to optimise muscle and joint use, and prevent overuse or disuse.
  • Correct maintenance of aids and prostheses.
  • Monitoring and early treatment of associated/contributing problems such as:

Further reading & references

  1. Trojan DA, Cashman NR; Post-poliomyelitis syndrome. Muscle Nerve. 2005 Jan;31(1):6-19. [abstract]
  2. EFNS guideline on diagnosis and management of post-polio syndrome; Report of an EFNS task force, European Federation of Neurological Societies (2006)
  3. Halstead LS, Silver JK; Nonparalytic polio and postpolio syndrome. Am J Phys Med Rehabil. 2000 Jan-Feb;79(1):13-8. [abstract]
  4. Howard RS; Poliomyelitis and the postpolio syndrome. BMJ. 2005 Jun 4;330(7503):1314-8.
  5. Khan F; Rehabilitation for postpolio sequelae. Aust Fam Physician. 2004 Aug;33(8):621-4. [abstract]
  6. Boone H; Problems experienced by polio survivors and suggested solutions. Presentation for occupational therapists, given at the Neurological Occupation Therapy Conference, October 2008.
  7. My Polio Life; A patient questionnaire providing baseline information and comparison charts, for use by polio survivors and their health professionals, Polio Survivors Network, 2007
  8. Boone H; When test results do not match important symptoms. Conference presentation, Post Polio Association of South Florida, Miami, 2007.
  9. Hildegunn L, Jones K, Grenstad T, et al; Perceived disability, fatigue, pain and measured isometric muscle strength in patients with post-polio symptoms. Physiother Res Int. 2007 Mar;12(1):39-49. [abstract]
  10. Davidson AC, Auyeung V, Luff R, et al; Prolonged benefit in post-polio syndrome from comprehensive rehabilitation: a pilot study. Disabil Rehabil. 2009;31(4):309-17. [abstract]
  11. Polio Outreach of Washington
  12. Lambert DA, Giannouli E, Schmidt BJ; Postpolio syndrome and anesthesia. Anesthesiology. 2005 Sep;103(3):638-44. [abstract]
  13. Howard RS, Davidson C; Long term ventilation in neurogenic respiratory failure. J Neurol Neurosurg Psychiatry. 2003 Sep;74 Suppl 3:iii24-30.
  14. Lincolnshire Post-Polio Information Newsletter. Volume 5, issue 9, June 2006. Issue covering respiratory problems.
Original Author: Dr Colin TidyCurrent Version: Dr Colin TidyPeer Reviewer: Dr John Cox

Post Polio Litaff, Association A.C _APPLAC Mexico


From: Healthy Partnerships. Ontario: March of Dimes, 1995
By: Richard L. Bruno, Ph.D., Nancy M. Frick, Lh.D., Susan J. Creange, M.A., Todd Lewis, Ph.D., and Terry Molzen, M.S.

Fatigue is the most commonly reported, most debilitating and least studied Post-Polio Sequelae 

(PPS) affecting the nearly 2 million North American polio survivors.Among polio survivors, 91% reported new or increased fatigue, 41% reported fatigue significantly interfering with performing or completing work and 25% reported fatigue interfering with self-care activities (1,2).Fatigue was reported to be triggered or increased by physical overexertion in 92% and by emotional stress in 61%. Importantly, polio survivors distinguish between the physical tiredness and decreased endurance they associate with new muscles weakness, and a 'brain fatigue' that is characterized by problems with attention and thinking. Between 70% and 96% of polio survivors reporting fatigue complained of problems with concentration, memory, attention, word-finding, maintaining wakefulness and thinking clearly, with 77% percent reporting moderate to severe difficulty with these functions (3).

Problems with attention, memory and thinking suggest that the symptoms of post-polio fatigue cannot be explained merely by the poliovirus damaging anterior horn motor neurons (4). Autopsies performed fifty years ago on people who died after having had polio, whether they had paralysis or not, showed that the poliovirus almost always damaged specific areas in the brain (Figure 1).These damaged areas include the brain's activating system that keeps you awake and allows you to focus your attention. The poliovirus also damaged neurons that produce neurotransmitters, including the enkephalins and endorphins (called the 'body's own morphine') as well as dopamine and ACTH which activate the brain.
With poliovirus damaging the brain's activating system, you would expect that the original polio infection should cause brain activating problems. And, reports written during the polio epidemics did describe 'drowsiness,' lethargy, prolonged sleeping and even coma during the acute polio infection (7,12,21,22).One-third of patients with acute spinal, spinal and bulbar and even non-paralytic polio showed 'disorientation, apathy, pronounced sleep disorder (and) irritability' (4).These mental changes were associated with the abnormal slowing of brain wave activity on the electroencephalogram (EEG).Further, a high percentage of children clinically recovered from poliomyelitis insofar as motor disability is concerned, had qualitative difficulties in mental functioning such as 'fatiguability and fleeting attention' for months after the acute polio (5).
These reports of persistent drowsiness, fatigue and fleeting attention following the acute poliovirus infection are similar to polio survivors' recent complaints of late-onset fatigue and impaired attention (25).  And, both acute and late-onset post-polio fatigue are reminiscent of nearly two dozen outbreaks during this century of post-viral fatigue syndromes (PFS) that are related clinically, historically or anatomically to poliovirus infections (26-28).These relationships and recent studies comparing post-polio fatigue and chronic fatigue syndrome will be described in an attempt to understand the cause and treatment of post-polio fatigue.
Type II Poliovirus and Decreased Brain Activation.During the polio epidemics of the 1950's, there were several small outbreaks of patients having drowsiness, prolonged sleeping, slowing of brain waves, as well as some of the symptoms of both bulbar polio and Parkinson's disease (e.g., tremor and rigidity) (29-30).In 1952, Type II poliovirus was isolated from one group of patients having these symptoms and it was found that the neurons in their brain activating system had been damaged.
The association of decreased brain activation and Parkinson's disease symptoms remind Dr. Oliver Sacks of the 'sleeping sickness' patients with Parkinson's disease he described in his book Awakenings.The relationship between 'sleeping sickness,' Parkinson's disease and polio may be important for understanding post-polio fatigue, since all of these have conditions are associated with damage to a part of the brain activating system called the basal ganglia.For example, Parkinson's disease (PD) patients have severe damage to one of the basal ganglia, the substantia nigra (sub-STAN-sha NYE-gra), which produces the neurotransmitter dopamine (doe-PAH-mean).  PD patients often describe fatigue.'Excessive fatigue' was reported by 48% of PD patients in one study (40) while nearly one-third of PD patients reported that fatigue was their 'most disabling symptom' (39).As a matter of fact, one of the first descriptions of Parkinson's disease (41) could serve as a definition of post-polio fatigue, i.e., a syndrome 'characterized by a diminution of voluntary attention, spontaneous interest, initiative and the capacity for effort and work, with significant and objective fatiguability, and a slight diminution of memory' (38).
'Atypical Poliomyelitis' and Chronic Fatigue.Beginning in Los Angeles in 1934 and continuing for more than twenty years, there were over a dozen outbreaks of a disease that was at first thought to be poliomyelitis, was then called "abortive" or "atypical" poliomyelitis and finally named 'Myalgic Encephalomyelitis' (ME) (6).Like poliomyelitis, initial symptoms of ME included headache, neck pain, low-grade fever and muscle pain that were often followed by muscle weakness.Patients were excessively sleepy and had "conspicuous changes in their levels of concentration" that lasted for months after the initial illness.Slowing of the EEG similar to that seen inacute polio was also noted.
Unlike poliomyelitis, there were frequent complaints of numbness or tingling, usually no breathing problems, paralysis or muscle wasting and almost invariably no deaths.Also unlike poliomyelitis, recovery from the initial symptoms of ME sometimes required months with most patients being left with a marked "exhaustion and fatiguability" that were "always made worse by exercise (and) emotional stress.'Patients continued to have fatigue, excessive sleepiness, trouble concentrating, difficulty with word finding, memory and thinking for years after the acute episode.
Despite the differences between poliomyelitis and ME, an association with the poliovirus was suggested by the fact that, of the more than one dozen ME outbreaks before the introduction of the Salk vaccine, nine occurred during or immediately after outbreaks of polio and several involved hospital staff who cared for polio patients (7).
Type III Poliovirus and Chronic Fatigue in Iceland.A more direct association between the poliovirus and ME was seen in 1948 in Akureyri, Iceland.Patients there presented with fever, muscle pain and weakness and were at first diagnosed as having poliomyelitis.After about a month, this diagnosis was discarded as patients reported additional symptoms not typical of polio, including tingling, numbness, "nervousness" and "general tiredness."Also unlike poliomyelitis, no deaths were reported and poliovirus was never isolated from any of these patients.When patients were reexamined six years after their original illness, 72% still had chronic "nervousness and general tiredness' and 21% reported a of "loss of memory.'
It was suggested that either an 'unusual' and mild poliovirus or some unknown virus caused these symptoms that were called 'Akureyri Disease' but are more commonly referred to as 'Iceland Disease' (ID).Support for an "unusual" poliovirus as the cause came in 1955 (10).There was an extensive epidemic of poliomyelitis in Iceland caused by Type I poliovirus that coincided with and was followed by outbreaks of ID.Remarkably, two cities in which ID outbreaks were reported in 1955, as well as the area affected by the 1948 'Akureyri Disease' epidemic, were untouched by poliomyelitis.None of the children tested in the two ID-affected cities and only 13% of the children in Akureyri had antibodies to Type I poliovirus as opposed to 86% of the children tested in the polio epidemic areas.Further, following poliovirus immunization, children in one of the ID-affected cities demonstrated antibody titres to Type II and Type III poliovirus that were four and twenty-five times higher than titres in a city where ID had not been reported.It was concluded that Type I poliovirus was not the cause of ID, but the citizens of the ID-affected areas had previously been exposed to something that was immunologically similar to Type III poliovirus.
An interesting coda to these findings is the report that when an American airman who had contracted polio in the 1955 Iceland epidemic returned to Massachusetts, a small outbreak of ID and polio occurred (11).More recent support for a relationship between poliovirus and ME came in 1989 when a 'dangerously rising titre' to Type III poliovirus was documented in a patient who did not have polio but had been diagnosed with ME (12).
Post-Polio Fatigue and Chronic Fatigue Syndrome.A group of symptoms resembling ME was termed 'Chronic Fatigue Syndrome' (CFS) following a Nevada outbreak in 1984 (13).Like ME and post-polio fatigue, CFS is characterized by complaints of chronic fatigue and trouble with concentration, memory and word finding that are triggered or exacerbated by physical exertion and emotional stress.And, although polio survivors are on average at least ten years older than patients with CFS, the years of education, sex distribution, frequency of difficulty with concentration and psychological symptoms are nearly identical in the two groups (Table 1)(17,18,19).  However, unlike ME and PPS, CFS patients report recurring sore throat, swollen glands and fever, suggesting to some that CFS is caused by a recurring or chronic viral infection.It is important to keep in mind that there is no evidence that PPS is caused by a persistent infection by any virus, including poliovirus (14,15).
Polio Survivors CFS Patients

Polio Survivors
CFS Patients
Sample Size
54 (±11)
39 (±12)
College Graduates
% Female
111 (± 2)
111 (± 4)
Difficulty with:

Word Finding


does not impair functioning
limits only social activities
impairs work or self-care ability
Depressive Symptoms
Table 1. Comparison of demographic data and symptom frequency in polio survivors reporting fatigue and in patients with Chronic Fatigue Syndrome (CFS).
* : Bruno and Frick, 1987; ¥ : Bruno, et al., 1991; ¤: Bruno, et al., 1993; # : Buchwald, et al., 1992.
The recent occurrence of CFS has allowed it to be studied using techniques that were not available during the polio, ME and ID epidemics and now allow neuropsychologic, neuroanatomic and neuroendocrine comparisons between this newest PFS and post-polio fatigue.
Neuropsychologic Studies.Some of the subjective difficulties with attention and cognition in CFS patients and polio survivors have been confirmed with neuropsychologic testing. CFS patients and polio survivors with severe fatigue have been shown to have clinical impairments of attention and information processing speed (Table 1)(16,19).Polio survivors reporting severe fatigue required 23% to 67% more time to complete tasks requiring sustained attention and vigilance than did polio survivors with no or mild fatigue.In spite of these marked impairments of attention, CFS patients and polio survivors have been shown to have I.Q.s within the high normal or superior range and have higher than average levels of educational and professional achievement (Table 1)(17).Further, despite the high frequency of subjective complaints of memory impairment in CFS patients and in 87% of polio survivors reporting fatigue, verbal memory has been shown to be intact on testing in both groups (16,19,20).However, polio survivors have twice been shown to have trouble recalling visual information whether or not they report fatigue (7,16).
These findings indicate that fatigue in CFS patients and polio survivors is associated with impairment of attention and information processing speed but not of memory or thinking ability.Given the findings of frequent and severe poliovirus lesions in the brain's activating system, it was hypothesized that damage to the brain's activating system is responsible for both fatigue and impaired attention in polio survivors.
Brain Scan Studies.
To test this hypothesis, magnetic resonance imaging (MRI) of the brain was performed to look for evidence of poliovirus lesions in the brain's activating system.In a first study, small areas of hyperintense signal (which look like white spots) on MRI were seen in the brain's activating system and in the myelinated (insulated) neurons that connect the brain stem (at the bottom of the brain) to the cortex (the 'supercomputer' at the very top of the brain) in eleven of twelve polio survivors (1).In a second study, white spots were seen in 55% of polio survivors with fatigue but were not seen in any of the subjects without fatigue (Figure 2)(21).The presence of the white spots were not only related to increased fatigue severity, but also to problems with memory, thinking clearly, mind wandering, attention and concentration.
Finding white spots on MRI supports the theory that fatigue and problems with attention in polio survivors may be related to damage the poliovirus did to the brain activating system.This conclusions is supported by a number of other studies that have shown a relationship between white spots on MRI, fatigue and problems with attention.Notably, white spots have been seen in between 40% and 100% of CFS patients (13) and even in healthy elderly adults who have problems with attention similar to those seen in CFS patients and polio survivors (22).
The figure is unavailable from the source document
Figure 2. A 24 mm2 focus of hyperintense signal (arrow) in the centrum semiovale in a 50 year old female polio survivor reporting moderate daily fatigue and frequent problems with concentration, thinking clearly, short term memory and staying awake (putamen lesion not seen in this view).
Hormonal Studies.The association of white spots in the brain activating system with the symptoms of post-polio fatigue suggested that the effects of poliovirus on other brain areas might also be evident in polio survivors.  For example, poliovirus lesions were often seen on autopsy in the hypothalamus (hypo-THAL-ah-mus), the brain area that automatically controls the body's internal environment and its response to stress.
To test the functioning of the hypothalamus, we measured polio survivors' blood concentrations of ACTH (a-DRE-no cor-ti-co-TRO-pick hormone), one of the body's stress hormones whose release is triggered by the hypothalamus. ACTH was measured following an an overnight fast, which is a mild stress known to cause the release of ACTH (7).ACTH was increased  outside of the normal range (as it should be following stress) in polio survivors who reported mild fatigue. However, there was noACTH increase in subjects reporting severe daily fatigue.Further, the higher the ACTH level, the lower the subjects' reported fatigue and the less the difficulty with memory, word finding, muscle weakness and staying awake during the day.
These findings indicate that the hypothalamus had not been activated in the subjects with post-polio fatigue and that ACTH production is reduced in these individuals.This conclusion is interesting for two reasons.  First, ACTH has been found in humans to promote alertness, increase attention and decrease fatigue by directly stimulating the brain activating system. Thus, a decrease in ACTH production may prevent brain activation and contribute to the symptoms of post-polio fatigue.Decreased activation of the hypothalamus has already been found in patients with CFS and a decrease in ACTH stimulation of the brain has been suggested as a cause of CFS (23).
Second, a decrease in ACTH production may be caused by a decrease in production of its parent molecule, POMC.POMC also produces beta-endorphin (BAY-ta en-DOOR-fin) which along with the enkephalins (en-KEF-ah-lins) are 'the body's own morphine.'Since poliovirus also damaged the brain area that produces enkephalins, both beta-endorphin and enkephalin production may be reduced in polio survivors.A reduction in the body's own morphine would help to explain why polio survivors have a nearly doubled sensitivity to pain (1).
Taken together, these findings suggest a model for the cause of post-polio fatigue:
               Poliovirus damaged the brain activating system;
               MRI and hormonal findings suggest that damage to the brain activating system is present today in polio survivors;
               Neuropsychological testing shows impaired attention in patients with post-polio fatigue;
               Therefore, poliovirus damage to the brain's activating system may cause decreased brain activation, impair attention and generate the symptoms of post-polio fatigue.

While poliovirus damage to the brain activating system would be expected to causethe sleepiness, inattention and fatigue reported during the original polio infection, it is the recurrence of these symptoms, or their appearance decades after the acute infection, that are more difficult to explain.The emergence of fatigue decades after the acute polio may result from normal age-related changes in and loss of brain activating system neurons that had survived the acute polio infection, combined with an already decreased number of neurons as a result of the original poliovirus infection.Eventually, the loss of brain activating system neurons would decrease cortical activation, reduce attention and produce the symptoms of fatigue as polio survivors reach mid-life (1).The occurrence of these symptoms during physical or emotional stress in polio survivors may reflect the ability of stressors to uncover otherwise unseen damage in the brain activating system.
The findings presented above describe an intimate relationship between impaired attention and fatigue.However, difficulty with attention is not fatigue's only symptom.Even more disabling is the physical experience of fatigue: feelings of exhaustion, 'passivity and an aversion to continued effort' that generate an aversion to both mental and physical activity. However unpleasant these feelings are in man, passivity and aversion to activity have clear survival value, especially in organisms without conscious awareness that their attention and thinking speed are impaired. For example, an animal that continues to explore its environment even though its attention is impaired would be less able to direct attention on the goal of its exploration (e.g., searching for food) and would thereby waste already diminishing energy stores.More importantly, impaired attention could also render the animal unaware of dangers in its environment (e.g., a predator stalking the animal in search of itsfood). Thus, there would be survival value in a brain mechanism that monitors cortical activation, biases an animal toward stopping motor behavior and promotes rest when attention and thinking speed are impaired.
The Brain 'Listens' to Itself.Groups of neurons near the bottom of brain called the basal ganglia are in an ideal location to monitor the level of brain activation and stop an animal when it has too little attention to allow efficient and safe activity in its environment.All parts of the cortex connect to one of the basal ganglia, called the putamen (pew-TAY-men), which 'listens' to the activity level of the brain (24).If the brain is awake enough, the putamen allows us to focus attention, to move and to act.When the brain activating system turns down, the putamen stops the cortex from allowing us to move.Damage to the putamen in animals has been shown to slow movement, while damage to another of the basal ganglia, the substantia nigra, decreases or even stops movement and prevents us from focusing attention (7).
The importance of the basal ganglia - and especially the neurotransmitter dopamine - in focusing attention and allowing us to move is most evident in patients with Parkinson's disease (PD).PD patients, whose damaged substantia nigra neurons produce too little dopamine, show not only slowed movement and an inability to focus attention but also excessive and disabling fatigue (7, 38-41).And, remember Oliver Sacks' Awakenings patients whose damaged basal ganglia caused both Parkinson's disease and 'sleeping sickness.'
The Brain Fatigue Generator.It appears that the basal ganglia could produce the mental and physical symptoms of both normal and pathological fatigue.In normal fatigue, a long and hard day of work would slow the firing of brain activating system neurons.This decreased activity would impair attention and information processing ability recognized by humans as symptoms of fatigue) and produce a decrease in cortical activation that would slow the firing of putamen neurons, prevent the release learned motor behaviors and slow or stop activity (Figure 3).Humans would notice problems with focusing attention, feel an aversion to activity and would be able to move only with significant conscious effort.Animals would slow or even stop their activity.In both man and animals, rest or sleep would increase the firing of brain activating system neurons, restore cortical activation, increase the firing of putamen neurons and once again allow the release of motor behavior.
The figure is unavailable from the source document
Figure 3. A model for the brain fatigue generator.Fatigue would be produced by a reduction inreticular activating system (RAS) activity that would directly decrease cortical activation, impair attention and cognition and prevent the firing of putamen neurons (dark lines).The reduction in putamen activity would then inhibit the release of motor behavior, further decrease attention and produce the visceral feelings of 'exhaustion' and aversion to effort that accompany fatigue (stippled lines).
Pathological states such as chronic fatigue syndromes could be produced by viral damage to the brain activating system, putamen and/or dopamine-producing neurons.This damage would chronically reduce the firing of brain activating system and putamen neurons, decrease cortical activation and produce the symptoms of fatigue.Poliovirus would be expected to cause fatigue, impaired cortical activation and decreased attention since it damages all of these brain areas.
This description of the basal ganglia as the brain fatigue generator suggests that increasing brain levels of dopamine (the neurotransmitter that stimulates the basal ganglia) might 'turn on' the brain activating system, increase cortical activation and attention, release motor behaviors and reduce the symptoms of chronic fatigue.We are currently studying the use of a drug that stimulates dopamine receptors on brain neurons to treat post-polio patients whose fatigue has not responded to the current treatments of choice, i.e., adequate rest, energy conservation, the pacing of activities and reducing physical and emotional stress (2,17,27,28). Preliminary results show that fatigue, impaired attention and difficulty staying awake during the day decrease as the dose of the drug increases.
However, there is the very real danger that taking a drug that reduces fatigue will allow polio survivors to resume their hyperactive, Type A lifestyles (as they do now when they feel better following physical, occupational and psychological therapy for PPS) and further stress poliovirus-damaged, 'metabolically vulnerable' neurons in the brain and spinal cord.  Decreasing 'overuse abuse' will always be necessary to treat PPS, regardless of whether a drug is found that decreases the symptoms of fatigue.
It is also possible that damage to the basal ganglia and a lack of dopamine may be related to other PPS symptoms.Word finding difficulties, reported by 82% of polio survivors with fatigue, appear similar both to word finding problems reported by CFS patients and the 'tip-of-the-tongue' phenomena seen in PD patients (Table 1)(1,7).And, in a study we have just completed, polio survivors with severe fatigue had low scores on a test of word finding ability - scores that were identical to those in Parkinson' patients.
In addition, 63% of polio survivors report Generalized Random Myoclonus (GRM), the slow contraction or rapid twitching of hand, arm, trunk and leg muscles at night that disturb sleep in 33% of polio survivors (2).  GRM may provide more evidence that polio survivors have a brain dopamine shortage, since GRM are similar to 'periodic movements in sleep' seen in PD patients.
We continue to examine the possible role of the basal ganglia and dopamine in PPS to help identify the cause and treatment of not only post-polio fatigue, but also other PPS, CFS and to understand the neurophysiology of fatigue itself. ACKNOWLEDGEMENTS
The authors gratefully acknowledge the participation of the subjects, the support of the Joel Leff Charitable Trust and Deluxe Corporation, the continued support of the George Ohl, Jr. Foundation, and the efforts and expertise of Mary Ann Solimine, R.N., M.L.S., without whom this work would not have been possible. We also thank Drs. Leonard Kurland and Oliver Sacks for their criticisms of the manuscript and Esther Carlton of Nichols Institute who provided the 11:00 AM norms for cortisol and ACTH.
1.              Bruno, R.L., N.M. Frick J. Cohen.1991.Polioencephalitis, stress and the etiology of post-polio sequelae. Orthopedics. 14:1185-93.
2.              Bruno, R.L. N.M. Frick. 1987.Stress and 'Type A' behavior as precipitants of Post-Polio Sequelae.In Research and Clinical Aspects of the Late Effects of Poliomyelitis.L.S. Halstead and D.O. Wiechers, Eds. March of Dimes.White Plains, NY.
3.              Bodian, D.1949.Histopathological basis of clinical findings in poliomyelitis.Am. J. Med. 6: 563-578.
4.              Holmgren, B.E. 1952. Electro-encephalography in poliomyelitis.In Poliomyelitis. Lippincott.Philadelphia, PA.
5.              Meyer, E. 1947.Psychological considerations in a group of children with poliomyelitis.J. Pediatrics.31: 34-48.
6.              Gilliam, A.G. 1938.Epidemiological study of an epidemic, diagnosed as poliomyelitis, occurring among the personnel of the Los Angeles County General Hospital during the summer of 1934.U.S. Public Health Bull. (No. 240): 1-90.
7.              Bruno, R.L., Sapolsky, R., Zimmerman, J.R., N.M. Frick.1995.  The pathophysiology of central post-polio fatigue: A role for the basal ganglia in the generation of fatigue. Ann. NY Academy of Sciences. 753: 257 - 275.
8.              Sigurdsson, B., J. Sigurjonsson, H.J. Sigurdsson, et al.1950.  A disease epidemic in Iceland simulating poliomyelitis.Am. J. Hyg. 52:222-238.
9.              Sigurdsson, B. and K.R. Gudmundsson.Clinical findings six years after outbreak of Akureyri Disease. Lancet.i: 766-767.
10.           Sigurdsson, B., M. Gudnadotti G. Petursson.1958.Response to poliomyelitis vaccination.Lancet. i: 370-371.
11.           Hart, R.H.1969.Epidemic neuromyesthenia.N. Eng. J. Med.281:797.
12.           Hyde, B.M., J. Goldstein P. Levine, Eds.1992. The Clinical and Scientific Basis of ME/CFS.The Nightingale Research Foundation.  Ottawa, Ontario.
13.           Buchwald, D.P.R.,P.R. Cheney,D.L. Peterson, et al. 1992. A chronic illness characterized by fatigue, neurologic and immunologic disorders and active human herpesvirus type 6 infection.Ann. Int. Med. 116:103-113.
14.           Bruno, R.L. 1991. Post-Polio Sequelae.Orthopedics. 14: 1169-1170.
15.           Melchers, W., M. De Visser, P. Jongen, et al.1992.The postpolio syndrome:No evidence for poliovirus persistence.Ann. Neurol.  32:728-732.
16.           Bruno, R.L., T. Galski, J. DeLuca.1993.Neuropsychology of Post-Polio Fatigue.Arch. Phys. Med. Rehabil. 74: 1061-1065.
17.           Bruno, R.L. N.M. Frick. 1991. The psychology of polio as prelude to Post-Polio Sequelae. Orthopedics.14: 1185-1193.
18.           Bruno, R.L. 1991. Post-polio sequelae, chronic fatigue syndrome and chronic musculoskeletal pain:Coincidence or causal connections?N.J. Rehab. 5:4-8.
19.           DeLuca, J., S.K. Johnson B.H. Natelson.1993.Information processing efficiency in chronic fatigue syndrome and multiple sclerosis. Arch. Neurol.50: 301-304.
20.           Sandman, C.A., J.L. Barron, K. Nackoul, et al.1993.Memory deficits associated with chronic fatigue immune dysfunction syndrome.  Biol. Psychiatry. 33: 618-623.
21.           Bruno, R.L., J. Cohen, T. Galski N.M.Frick.1994.  The neuroanatomy of post-poliofatigue.Arch. Phys. Med. Rehabil. 75: 498-504.
22.           Junque, C., J. Pujol, P. Vendrell, et al.1990. Leuko-araiosis on magnetic resonance imaging and speed of mental processing.Arch Neurol.47:151-156.
23.           Demitrack, M.A., J.K. Dale, S.E. Straus, et al.1991.Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J. Clin. Endocrinology Metabolism.  73: 1224-1234.
24.           Denny-Brown, D. N. Yanagisawa. 1976.The role of the basal ganglia in the initiation of movement.In The Basal Ganglia.  M.D. Yahr, Ed. Raven. New York, NY.
25.           Friedman, J. H. Friedman.1993.Fatigue in Parkinson's disease. Neurology.43:2016-2018.
26.           Naville, F. 1922.Encephale.17:369-375.
27.           Young, G. 1991. Energy conservation, occupational therapy and the treatment of Post-Polio Sequelae.Orthopedics. 14:1233-39.
28.           Agree, J.C. A.A. Rodriguez.1991.Neuromuscular function in polio survivors.Orthopedics. 14:1343-1347.
Please address all correspondence and reprint requests to: Dr. Richard L. Bruno, Director Post-Polio Rehabilitation and Research Service, Kessler Institute for Rehabilitation, 300 Market Street, Saddle Brook, New Jersey 07663. 1 (800) 648-0296 (x6057).

Post Polio Litaff, Association A.C _APPLAC Mexico

Polio Film

Entradas populares



México Post Polio Una Vida Un Camino Una Experiencia

Post Polio LITAFF A.C.
Postpoliolitaff.- Asociación Post Polio Litaff A.C Primera Organización oficial sobre Síndrome de Post Poliomielitis En México.

Polio y Efectos Secundarios SPP
- See more at:


Salk Institute

Polio Video

Polio Lungs

Polio Reinders

March Of Dimes Polio History

Erradicación de La poliomielitis

Blog Archive

Search This Blog

No more Polio

Dr. Bruno